AlphaMaven AlphaMaven

RA Capital expands to Shanghai, pushes back on Washington’s China biotech curbs - South China Morning Post

Reported by Scmp
Nov 19, 2026· 2 min read
Save Post LinkedIn Email
Key Takeaways
  • • RA Capital, a Boston-headquartered healthcare-focused venture capital firm, opened a Shanghai office in mid-October, according to partner Josh Resnick.
  • • The Shanghai team has 12 China-based staff, including four investment professionals who began working in the country in the past few months.
  • • The expansion comes as the US Treasury proposes curbs on American investment in Chinese biotech firms, a move the firm's leadership appears to be pushing back against.
  • • RA Capital and peers told Treasury in a comment letter that the draft rule will not slow China biotech, which will have ample capital without US equity investment.
Summary
RA Capital, a prominent healthcare-focused US venture capital firm headquartered in Boston, has expanded its China footprint with a new Shanghai office aimed at tapping innovation in the Chinese biotech ecosystem. Partner Josh Resnick said in an interview with the South China Morning Post on Wednesday that the firm now has 12 China-based staff members, including four investment professionals who started working in the country in the past few months. The office was opened in mid-October, according to Resnick.

The expansion comes as US firms navigate Washington's escalating scrutiny of cross-border deals. Publisher coverage indicates the US Treasury has proposed curbs on American investment in Chinese biotechnology companies, part of a broader push by lawmakers to limit the rise of China's biotech sector. Experts quoted by Fierce expressed concern about how the proposed COINS Act treats the deal structures that sustain biopharma dealmaking. A licensing exemption in the proposed rules has sparked debate within the industry over protectionism and venture capital deals, according to separate coverage.

RA Capital has publicly engaged with the rulemaking. In a comment to Treasury, the firm and its peers argued that the draft rule will not slow China biotech, which will have plenty of capital even without US equity investment. The firm has also been active in deal structuring, with publisher coverage noting a SPAC transaction aimed at merging a latest special purpose acquisition company with a Chinese biotech, according to a securities filing. Coverage also referenced a layoff at the firm's incubator unit amid the industry shift.

Analysts cited in coverage warn that the proposed restrictions could shut US investors out of China's innovation boom and slow global drug development advances, while licensing deals remain untouched for now.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Scmp RA Capital expands to Shanghai, pushes back on Washington’s China biotech curbs - South China Morning Post